Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)
Open Access
- 8 March 2010
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 101 (6), 476-480
- https://doi.org/10.1002/jso.21522
Abstract
Background and Objectives Chemoembolization with doxorubicin drug eluting beads (DEB) is a novel locoregional treatment modality for unresectable hepatocellular carcinoma (HCC). Initial animal studies and clinical trials suggest that treatment with DEB may provide safer and more effective short‐term outcomes than conventional chemoembolization. Current study explores long‐term survival benefits. Methods Consecutive patients who received transcatheter therapy with DEB or conventional chemoembolization as sole therapy between 1998 and 2008 were studied. Statistical analysis was performed using Kaplan–Meier estimator with log‐rank testing, chi‐squared, and independent t‐tests. Results Seventy‐one patients were included in this study, 45 (63.4%) received therapy with DEB (group A) and 26 (36.6%) underwent conventional chemoembolization (group B). Median survival from diagnosis of HCC in groups A and B were 610 (351–868) and 284 days (4–563; P = 0.03), respectively. In Okuda stage I, survival in groups A and B were 501 (421–528) and 354 days (148–560, P = 0.02). In Child–Pugh classes A and B, survival in groups A and B were 641 (471–810) and 323 days (161–485, P = 0.002). Median survival in patients with Cancer of Liver Italian Program (CLIP) score ≤3 in groups A and B were 469 (358–581) and 373 days (195–551, P = 0.03). NCI CTCAEv3 Grade 5 clinical toxicity was similar. Conclusions In our study, transcatheter therapy with DEB offers a survival advantage over conventional chemoembolization for patients with unresectable HCC. J. Surg. Oncol. 2010; 101:476–480.This publication has 17 references indexed in Scilit:
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V StudyCardioVascular and Interventional Radiology, 2009
- Hepatocellular Carcinoma: Epidemiology and Molecular CarcinogenesisGastroenterology, 2007
- Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokineticsJournal of Hepatology, 2007
- Pharmacokinetic and Safety Study of Doxorubicin-eluting Beads in a Porcine Model of Hepatic Arterial EmbolizationJournal of Vascular and Interventional Radiology, 2006
- New Intra-arterial Drug Delivery System for the Treatment of Liver Cancer: Preclinical Assessment in a Rabbit Model of Liver CancerClinical Cancer Research, 2006
- AASLD practice guidelines: Evaluation of the patient for liver transplantationHepatology, 2005
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- Chemoembolization of Hepatocellular CarcinomaJournal of Vascular and Interventional Radiology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002